Porcine reproductive and respiratory syndrome virus (PRRSV) is one of the most important swine viral pathogens, and has caused significant economic losses to the swine industry worldwide. Characterization of field isolates suggested that PRRSV are genetically diverse, and this genetic variation increases the difficulty of developing effective vaccines. Based on significant sequence differencesPRRS viruses are grouped into two distinct genotypes, European isolate (Lelystad virus, LV) and North American isolate (VR-2332)PRRSV has two major structural proteins, GP5 and M, encoded by ORFs 5 and 6, respectively. GP5, the most important neutralizing antigen of PRRSV, has the highest genetic diversity among isolates. And, recent studies in Yorkshire × Landrace crossed and outbred pigs, showed that there are two immuno-dominant T-cell epitopes derived from the GP5 protein: L117AALICFVIRLAKNC and K149GRLYRWRSPVII/VEK. The M protein, which contains highly conserved amino acid sequences, also has very good immunogenicity and is associated with protection against PRRSV infection. DNA vaccinations have also revealed that M is the most potent inducer of T lymphocyte proliferation.
At present, effective vaccination strategies for the prevention and control of PRRSV infection are not available. Vaccines based on inactivated PRRSV virus have been ineffective at inducing protective immune responses. Live-attenuated PRRSV vaccines can provide protection against this pathogen, but have been observed to revert to virulence, restricting the application of this vaccination approach. The rational development of future PRRSV vaccines will necessitate a systematic understanding of the protective humoral and cellular immune responses that occur during PRRSV infection, and should aim to induce a broad immune responses that accommodates the plasticity of the major antigenic sites. Recent research has indicated that cell-mediated immunity may play a very important role in the clearance of PRRSV. Major histocompatibility complex (MHC) I restricted cytotoxic T lymphocytes (CTLs) can kill virus-infected cells and eliminate potential sources of new virus. Hence, identification of CTL epitopes is crucial in the design of synthetic vaccines, and a number of studies have successfully identified pathogen-derived T cell epitopes.
Unlike many other pathogens, there is limited knowledge of the specific PRRSV-derived peptides targeted by T-cells. In the current study, we report the identification of CTL epitopes from the PRRSV (Ch-1a strain) M protein in a mouse model. We screened peptides derived from the PRRSV M protein for their ability to induce interferon (IFN)-γ in splenocytes harvested from BALB/c mice following DNA vaccination and a booster vaccination with recombinant vaccinia virus expressing M protein. The screen identified two peptides that elicited IFN-γ production in CD3+CD8+ splenocytes of vaccinated mice. A multiple amino acid sequence alignment among different PRRSV M proteins indicates that these two peptides are strongly conserved across multiple PRRSV strains and therefore should be considered for further research.
2.1. Viruses and cell lines
The PRRSV Ch-1a strain, the vaccinia virus WR strain, and the Akabane virus OBE-1 strain were part of our laboratory collection. The former was propagated in Marc-145 cells, and the latter two were propagated in BHK-21 cells, respectively, and these two cell lines were cultured in DMEM (Invitrogen) supplemented with 10% of fetal calf serum (FCS, Invitrogen) in a humidified 37°C, 5% CO2 incubator.
2.2. Cloning of PRRSV M and murine ubiquitin (Ub) genes
Total RNA was extracted from the PRRSV CH-1a strain and the spleens of BALB/c mice. Full length cDNAs were amplified based on the complete open reading frames (ORFs) of M and ubiquitin (Ub) following reverse transcription (GenBank accession numbers AY032626 and AZ033428) using the M-F and M-R primers pair or the Ub-F and Ub-R primer pair (Table 1). The full length cDNAs were cloned into the pMD18-T vector (TaKaRa) and are referred to as pMD-M and pMD-U, respectively.
2.3. The expression of a truncated PRRSV M gene
An indirect enzyme-linked immunosorbent assay (iELISA) method was established to evaluate specific antibody against M protein. A truncated M protein (85-174aa), which was used as the coating antigen, was expressed and purified using a prokaryotic expression system. The truncated M gene cDNA was amplified from pMD-M using the truncated-M-F and truncated-M-R primers (Table 1), ligated into pGEX-6P-1 (GE Healthcare), and subsequently named pGEX-M. For protein expression, pGEX-M was transformed into E.coli BL21 (DE3) and recombinant protein expression was induced with 0.5 mM IPTG. The samples were harvested by centrifugation and the pellets were resuspended with phosphate buffered saline (PBS, PH 8.0). After being analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and Western blot with anti-PRRSV-M monoclonal antibody (our laboratory collection), the fusion-expressed truncated M protein was purified by GST tag according to the manufacturer's instructions (GE Healthcare). Finally, the concentration of the purified protein was determined using a Bradford kit (Bio-Rad) according to the manufacturer's instructions.
2.4. Construction of the eukaryotic expression plasmid pVAX1-Ub-M
The Ub and M genes were fused using splicing by overlapping extension PCR (SOE-PCR). The Ub and M genes were amplified from pMD-U and pMD-M with the primer pairs Ub-F and Fusion-M-Ub-R and Fusion-M-Ub-F and M-R, respectively (Table 1). The fusion gene product, referred to as Ub-M, was amplified from the purified PCR products with Ub-F and M-R and inserted into the eukaryocyte expression vector pVAX1, and was named pVAX1-Ub-M.
2.5. Expression of pVAX1-Ub-M in vitro
In vitro expression of the Ub-M was demonstrated by transient transfection of BHK-21 cells using FuGene 6 (Roche) according to the manufacturer's instructions. Ub-M protein expression was detected by indirect immunofluorescence analysis (IFA). An anti-PRRSV-M monoclonal antibody and a FITC-conjugated rabbit anti-mouse IgG secondary antibody (Sigma) were used for IFA detection of M protein. Fluorescence was observed using a fluorescence microscope (LEICA DM IRE2).
2.6.1. Construction of the transferring plasmid pSC11-M
The transferring vector pSC11 (our laboratory collection), which is composed of the early promoter P7.5 and late promoter P11 of vaccinia virus, and the LacZ and Amp genes controlled by the promoter P11 as the reporter genes, was used in this study. To construct the transferring vector pSC11-M, the complete M gene was amplified with the pSC11-M-F and pSC11-M-R primer pair (Table 1) and inserted into the pSC11. The primer P7.5-F (Table 1), derived from promoter P7.5 sequence, was used for directional identification and the positive clones, which were subsequently named pSC11-M.
2.6.2. Homologous recombination and selection of the recombinant virus
Homologous recombination was performed by lipofectin-mediated co-transfection of the transferring plasmid pSC11-M and the WR strain vaccinia virus into 80% confluent TK-143 cells cultured in MEM medium containing 25 μg/ml BrdU (Sigma). The viruses were collected after the appearance of cytopathic effect (CPE), and recombinant vaccinia virus was purified according to the expression of LacZ gene.
2.7.1. Western blot analysis of the recombinant virus
Western blot analysis was performed as described previously. Briefly, a BHK-21 cell layer was infected with rWR-PRRSV-M recombinant vaccinia virus or the vaccinia virus WR strain at a multiplicity of infection (MOI) of 0.1. Cells were harvested 3 days post-infection, and total cell lysates were prepared with lysis buffer (10 mM Tris-Cl pH 7.4, 1 mM MgCl2, 0.5% NP40, 20 μg/ml DNase I). Cell lysates were separated by SDS-PAGE and were subsequently transferred to a membrane for Western blot analysis using an anti-PRRSV-M monoclonal antibody, HRP-conjugated goat anti-mouse IgG secondary antibody (Bio-Rad), and DAB substrate. The positive recombinant virus was named rWR-PRRSV-M.
2.7.2. IFA of the recombinant virus
The expression of M was further confirmed by IFA. Briefly, BHK-21 cells were infected with either rWR-PRRSV-M or the vaccinia virus WR strain when the BHK-21 cells reached 70-80% confluence in a 24-well plate. M protein expression was evaluated by IFA 3 days post infection using the anti-PRRSV-M monoclonal antibody followed by a FITC-conjugated rabbit anti-mouse IgG secondary antibody (Sigma). Specific fluorescence was observed using a fluorescence microscope (LEICA DM IRE2).
2.8. Prediction and synthesis of M protein CTL epitopes in BALB/c mice
The sequences of M were screened for potential H2-Kd/H2-Dd/H2-Ld 9-mer epitopes using the algorithms from the SYFPEITHI website, the HLA peptide binding prediction website (BIMAS) and PREDBALB/c. The 27 peptides (Table 2), with highest binding score (BS) as predicted by each algorithm, were synthesized by Scilight Biotechnology LLC (Beijing, China) and purified to a purity > 95% using high performance liquid chromatography (HPLC).
2.10. Vaccination using a DNA prime-recombinant vaccinia virus boost strategy
All animal experiments were performed according to national and institutional guidelines. One hundred and ninety female BALB/c mice (Vital River Laboratory Animal Technology Co., Beijing, China) were maintained in isolation cages at the Experimental Animal Center of Harbin Veterinary Research Institute (Harbin, China). Mice were divided into three groups: the pVAX1-Ub-M vaccination group (n = 120), the pVAX1 control vaccination group (n = 35) and the PBS control vaccinated group (n = 35).
The plasmid DNA used for immunization was purified using the EndoFree Mega plasmid preparation kit (Qiagen). The pVAX1-Ub-M and pVAX1 cohorts were intramuscularly (i.m.) vaccinated with 100 μg pVAX1-Ub-M or pVAX1 plasmid DNA in 100 μl PBS, respectively. The PBS control group received an i.m. injection of 100 μL PBS. Each group was vaccinated four times at 3-week intervals. To enhance the specific CTL responses to M protein, the mice received an intraperitoneal (i.p.) injection containing 0.1 MOI of rWR-PRRSV-M on day 7 following the fourth DNA vaccination. At the same time, five mice from the pVAX1 and PBS vaccination groups were also inoculated intraperitoneally with 0.1 MOI of rWR-PRRSV-M on day 7 following the fourth vaccination in order to compare the specific antibody raised against M protein of different experimental groups following vaccination with rWR-PRRSV-M. All procedures were conducted with the protocols approved by Experimental Animal Center of Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS).
2.11. ELISA antibody response in mice after immunization
To investigate the specific antibody response, serum samples was obtained from vaccinated mice 7 days after each DNA vaccination and 3 days after boosting with rWR-PRRSV-M. An iELISA was performed according to methods described previously. The purified M protein was used as the coating antigen, the tested sera applied at a 1:10 dilution, and an HRP-conjugated goat anti-mouse IgG antibody (Bio-Rad) used as the secondary antibody. The microplates were developed using ortho-phenylene diamine (OPDA, AMERSCO) and H2O2 for 10 min, after which the reaction was stopped by the addition of 1 M H2SO4. Finally, the optical density (OD) was read at 492 nm. An anti-PRRSV-M monoclonal antibody was used as a positive control. Serum containing antibodies against Akabane virus and the sera of control group mice served as negative controls.
2.12. In vitro stimulation of splenocytes
Isolated splenocytes were added to U-bottomed 96-well plates (Corning Inc) at 106 cells/well in 100 μL complete RPMI-1640 medium supplemented with 10% FCS. The cells were then mixed with 100 μl media containing a nonamer peptide derived from PRSSV M protein at 20 μg/ml, or phorbol-12-myristate-13-acetate (PMA 10 ng/mL) and ionomycin (500 ng/mL) as a positive control. Cells incubated in medium alone or with a peptide derived from the infectious bronchitis virus (IBV) H52 strain were used as negative controls. Following a 12 h incubation at 37°C, 10 uM monensin (Sigma) was added and the splenocytes were incubated for an additional 4 h at 37°C before staining.
2.13. Surface antigen staining and intracellular cytokine staining (ICS)
The number of CD3+CD8+ T cells producing IFN-γ on days 3, 5 and 12 after boosting with rWR-PRRSV-M was determined using flow cytometric analysis. ICS analysis was performed using a FACSCalibur flow cytometer (BD) according to the methods described previously. Twenty mice were tested from the group vaccinated with pVAX1-Ub-M, and five mice from the groups vaccinated with pVAX1 and PBS were tested at each time point. The splenocytes from each vaccination group were counted, pooled, and stimulated in vitro with M protein-derived peptides, as detailed in section 2.12. Ten thousand CD3+ T lymphocytes were acquired per sample and the number of IFN-γ-secretion CD3+CD8+ T cells were enumerated. The CD3+CD8+ lymphocytes that expressed IFN-γ following peptide stimulation were considered to be peptide-specific CTLs. Specific CTL responses were evaluated as the increase in the number of CD3+CD8+IFN-γ+ cells. Reagents used include PerCP-conjugated CD3e, PE-conjugated CD8a and FITC-conjugated IFN-γ, and BD Cytofix/Cytoperm™, all purchased from Becton, Dickinson & Co (BD).
2.14. Confirmation of ICS results by ELISpot assay
To further confirm the results of the ICS, the other sixty mice from the group vaccinated with pVAX1-Ub-M and thirty mice from the groups vaccinated with pVAX1 and PBS were tested by the IFN-γ ELISPOT assay at three different time points (as detailed in section 2.13). Data are expressed as the number of IFN-γ-secreting cells per two hundred thousand splenocytes. Peptide-specific IFN-γ ELISPOT responses were considered to be positive if the response (minus media background) was ≥ 3-fold above the media response and ≥ 50 spot-forming cells (SFC)/2 × 105 splenocytes were registered.
2.15. Statistical analysis
The iELISA results, the percentage of IFN-γ positive CD3+CD8+ T lymphocytes and the number of spots per 2 × 105 splenocytes were analyzed using the analysis of variance (ANOVA), and a probability value below 0.05 was considered significant.
3.1. The truncated expression of PRRSV M
As the full-length M protein is difficult to express in vitro, we expressed a truncated version of M that lacks 84 hydrophobic amino acids at the N-terminus. SDS-PAGE analysis showed that cells transformed with the pGEX-M expression vector produced a large amount of protein with a molecular mass of approximately 36 KDa, consistent with the expected molecular weight of the truncated M protein fused with a GST tag (data not shown). Western blot analysis using an anti-PRRSV-M antibody confirmed the expression and identity of the truncated M protein fused with a GST tag (Additional file 1, Fig. S1).
3.2. Expression of pVAX1-Ub-M in vitro
The Ub Proteasome Pathway (UPP) is the principal mechanism for protein catabolism in the mammalian cytosol and nucleus. In order to enhance the Ub-mediated degradation efficiency of M protein, we expressed a Ub-M fusion protein in BHK-21 cells using the eukaryotic expression plasmid pVAX1-Ub-M, in which the Ub coding sequence was fused in-frame with the PRRSV M coding sequence. Following transient transfection of BHK-21 cells with the pVAX1-Ub-M plasmid, the Ub-M fusion protein was expressed and accumulated predominantly in the cytoplasm (Additional file 2, Fig. S2).
3.3. Identification of the recombinant vaccinia virus
Immunization strategies that prime and boost with recombinant DNA vectors encoding antigens have been shown to elicit T-cell immunity against HIV in non-human primates, and more recently, in humans. Therefore, we used a DNA vector encoding the PRRSV M protein to immunize mice in order to generate and characterize M protein-reactive CD8+ T cells. The recombinant vaccinia virus rWR-PRRSV-M drove expression of an M protein with the expected molecular weight when transfected into BHK-21 cells (Additional file 3, Fig. S3). IFA confirmed expression of M protein following transfection of BHK-21 cells, and revealed M protein accumulation in the cytoplasm (Additional file 4, Fig. S4).
3.5. Detection of antibodies against M protein by ELISA
M protein-specific serum antibody increased steadily from the second to the fourth DNA vaccination with the pVAX1-Ub-M vector which drives M protein expression in vivo (Additional file 5, Fig. S5), indicating that DNA vaccination elicited M protein-specific immune responses as expected. A subsequent booster vaccination with the recombinant vaccinia virus, rWR-PRRSV-M, elicited a further increase in PRRSV-specific antibody (P < 0.01, Additional file 5, Fig. S5). In contrast, control mice vaccinated with pVAX1-only or PBS-only did not show significant increases in M protein-specific antibody titers after the booster vaccination with rWR-PRRSV-M (P > 0.05, Additional file 5, Fig. S5). Overall, mice vaccinated with pVAX1-Ub-M generated significantly higher M protein-specific antibody titers compared to mice vaccinated with pVAX1 or PBS (P < 0.01, Additional file 5, Fig. S5). These results indicate that rWR-PRRSV-M amplifies the protective effects of DNA vaccination and reveals the advantage of this priming-boosting strategy. DNA vaccination with pVAX1-Ub-M likely drives the differentiation of memory B cells which are subsequently activated by rWR-PRRSV-M following the booster immunization, resulting in increased M-specific antibody titers. Mice vaccinated with PBS and pVAX1 would not be expected to generate M protein-reactive memory B cells, accounting for a less pronounced increase in M protein-specific antibody titers following rWR-PRRSV-M innoculation.
3.6. Identification of PRRSV-M CTL epitopes by ICS and ELISPOT
In this study we identified potential CTL epitopes in BALB/c mice vaccinated with pVAX1-Ub-M and boosted with rWR-PRRSV-M. The frequency and number of CD3+CD8+ T cells that produced IFN-γ following stimulation with peptides derived from PRSSV M protein was enumerated using ICS and ELISPOT assays. Using these approaches, we identified two peptides from PRSSV M protein that elicited IFN-γ production from the splenocytes of vaccinated mice. As shown in Figure 1, intracellular IFN-γ staining following stimulation of splenocytes from vaccinated mice with the peptide K93FITSRCRL and F57GYMTFVHF revealed a population of IFN-γ producing CD8+ T cells comprising 4-5% of the total CD3+ splenocyte population. In contrast, unstimulated splenocytes and splenocytes exposed to an irrevelant peptide did not contain a population of IFN-γ producing CD8+ T cells (Figure 1, panel B and C). Consistent with the ICS data, peptides K93FITSRCRL and F57GYMTFVHF elicited IFN-γ production from splenocytes of vaccinated mice when measured by ELISPOT, whereas unstimulated splenocytes and splenocytes stimulated with an irrelevant peptide did not reveal IFN-γ producing cells (Figure 2). The K93FITSRCRL and F57GYMTFVHF PRSSV M protein peptides were identified bioinformatically as H-2Kd and H-2Dd restricted CTL epitopes (Table 2).
Specific increases in the number of cells producing IFN-γ following stimulation with the peptides "K93FITSRCRL" and "F57GYMTFVHF" was observed by day 3 after the booster vaccination with rWR-PRRSV-M (Figure 1 and 2). Furthermore, splenocytes from mice vaccinated with pVAX1-Ub-M responded strongly to "K93FITSRCRL" and "F57GYMTFVHF", but not other M protein-derived peptides, at all time points tested following the booster vaccination with rWR-PRRSV-M. When the same pattern of reactivity on three different time points after boosting with rWR-PRRSV-M within each vaccination group were analyzed statistically using ANOVA analysis, statistically significant differences were noted for the peptides "K93FITSRCRL" and "F57GYMTFVHF" when compared to the other peptides tested among mice vaccinated and boosted with pVAX1-Ub-M and rWR-PRRSV-M, respectively (P < 0.01, Figure 3A and 3B). Conversely, and confirming the specificity of these responses, no difference among the stimuli was observed with mock-vaccinated (pVAX1) mice and naïve mice (data not shown).
It is important to recognize that the ICS assay calculates the percentage of IFN-γ+ cells among CD3+ T cells in the spleen (4-5%), whereas the ELISPOT assay assesses the number of IFN-γ+ cells among all splenocyte cell types (0.05%), and cannot definitively assign the production of IFN-γ to a particular cell type. Thus, the two assays use different denominators in calculating the frequency of IFN-γ+ production by splenocytes. Importantly, each method clearly identified K93FITSRCRL and F57GYMTFVHF as the only two peptides from a panel of 27 that elited significant IFN-γ production from the splenocytes of vaccinated mice.
In this study we used BALB/c mice as a model system to identify CTL epitopes in the M protein of PRSSV to circumvent limitations derived from shortages of inbred pigs and a paucity of reagents to evaluate porcine immune responses. The identification of PRSSV CTL epitopes in BALB/c mice allow for the future generation of reagents, such as MHC class I: peptide staining reagents, that will enable the in-depth investigations of CD8+ T cell responses during PRSSV infection and immuinization. Whether these two epitopes can bind the SLA class I molecules of pigs remains to be determined. In some cases, specific peptide epitopes are known to be recognized by cytotoxic T cells in different animal species. For instance, the core region of HCV contains an epitope that is recognized by cytotoxic T cells of both mice and humans. Further research on the role of these peptide epitopes in different species is ongoing in our laboratory.
In conclusion, we identified peptides "K93FITSRCRL" and "F57GYMTFVHF" from the M protein of PRSSV as H-2Kd and H-2Dd restricted CTL epitopes, respectively. In this study, we also developed a mouse model of PRRSV infection and this will undoubtedly contribute to our understanding of the cell-mediated immune responses to PRRSV.
The authors declare that they have no competing interests.
DLW and GLL gave me the idea of this study. WJZ and YL participated in the design and conducted the majority of the experiments as well as drafted the manuscript. TGT helped revise the manuscript and participated in the first stage of the experiments. YB and QW participated in the prediction of CTL epitopes and analyzed the data. YHX, NHL and TY participated in the sequence alignment. ZGB provided the expression system of recombinant vaccinia virus, and GZT provided the PRRSV Ch-1a strain. All the authors read and approved the final manuscript.